- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05224986
라이프스타일 패턴과 혈당 조절
The goal of the proposed study is to evaluate the feasibility and initial efficacy of stabilizing lifestyle behaviors to improve glucose control and body composition in patients with pre-diabetes.
The investigator proposes that following stable lifestyle behaviors will improve patients' glucose control, body composition, and liver fat. The results from this study has the potential to impact clinical practice and patient care.
연구 개요
상세 설명
Variability in lifestyle behaviors has been associated with adverse health, specifically poor glucose control. The project proposes to test whether reducing this variability improves glycemia in patients with pre-diabetes. If successful, this simple positive lifestyle message to keep stable behaviors has the potential to improve the health of millions of adults worldwide.
This project will enroll participants with pre-diabetes who have erratic lifestyle behaviors and randomize them to either maintain their usual habits (control group) or stabilize their behaviors (stability group). Both groups will be followed for 12 weeks. Before the start of the 12-week period, all participants will track their sleep for 2 weeks and will wear a glucose monitor to measure their glucose levels. At the start and end of the 12-week period, they will come to the research lab to undergo a glucose tolerance test. This test will measure how their body reacts to a glucose load. They will also undergo magnetic resonance imaging and spectroscopy scanning. This scan will provide information on body composition and liver fat content.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
New York
-
New York, New York, 미국, 10032
- Columbia University Irving Medical Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Pre-diabetic kg/m2 (hemoglobin A1c 5.7-6.9%)
- 25 years or older
- BMI between 25-39.9 kg/m2
- Sleep duration ≥6 hours a night assessed with wrist actigraphy (for 14 nights)
- Variable bedtime, SD≥45 minutes.
Exclusion Criteria:
- Chronic Kidney Disease (GFR<60)
- Uncontrolled hypertension (≥160/100 mmHg)
- Obstructive Sleep Apnea
- Psychiatric or neurological disorder
- Prevalent cardiovascular disease
- Dyslipidemia (triglycerides≥200 mg/dL)
- Medications that affect insulin sensitivity, glucose concentrations, and body weight
- Non-day or rotating shift workers
- Travel across time zones
- Active participation in weight loss program or within past 3 months
- Current or past alcohol/drug abuse
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
간섭 없음: Variable Schedule
Participants randomized to Variable Schedule (VS) will be asked to maintain their usual habits for 12 weeks. |
|
|
실험적: Fixed Schedule
Participants randomized to Fixed Schedule (FS) will be asked to stabilize their lifestyle behaviors for 12 weeks. |
Participants will be asked to maintain a fixed schedule for 12 weeks. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Adipose Tissue Measurement - Total
기간: 12 weeks
|
Measuring total adiposity. Measured by MRI, includes both subcutaneous and visceral adipose tissue. |
12 weeks
|
|
Adipose Tissue Measurement - Subcutaneous
기간: 12 weeks
|
Measurement of subcutaneous adiposity using MRI. |
12 weeks
|
|
Adipose Tissue Measurement - Visceral
기간: 12 weeks
|
Measurement of visceral adiposity using MRI. |
12 weeks
|
|
Glucose Area Under Curve
기간: 12 weeks
|
Testing glycemic control.The primary outcome variable is glucose under the curve during the oral glucose tolerance test. |
12 weeks
|
|
Mean Amplitude of Glycemic Excursion and Standard Deviation of Mean Glucose
기간: 12 weeks
|
Testing glucose variability. The primary outcome variables are mean amplitude of glucose excursion and standard deviation of average glucose. |
12 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Liver Fat Content
기간: 12 weeks
|
This is to assess liver fat measured by MRS and MRI in %. |
12 weeks
|
|
Disposition Index
기간: 12 weeks
|
This is to assess disposition index, measured using HOMA-IR. The disposition index is the product of the insulogenic index and homeostatic model of assessment for insulin resistance. |
12 weeks
|
|
Short-term Change in Glycemia
기간: Baseline, up to 12 weeks
|
Assessing whether short-term glycemia is changed by measuring fructosamine using two-sample t-tests. |
Baseline, up to 12 weeks
|
|
Endothelial cell inflammation (sub-set, n≤10)
기간: Baseline, 12 weeks
|
NF-κB nuclear fluorescence area for pilot study. |
Baseline, 12 weeks
|
|
White blood cells
기간: Baseline, 12 weeks
|
Leukocytes and neutrophils |
Baseline, 12 weeks
|
|
Long-term Change in Glycemia
기간: Baseline, 12 weeks
|
Assessing whether long-term glycemia is changed by measuring hemoglobin A1c using two-sample t-tests. |
Baseline, 12 weeks
|
|
Endothelial cell oxidative stress (sub-set, n≤10)
기간: Baseline, 12 weeks
|
redox sensitive fluorogenic probe fluorescence intensity for pilot study. |
Baseline, 12 weeks
|
공동 작업자 및 조사자
협력자
수사관
- 수석 연구원: Marie-Pierre St-Onge, Columbia University
- 수석 연구원: Blandine Laferrere, Columbia University
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- AAAT8914
- R01DK128154 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .